Skip to content

FDA Clears OcuMet Beacon for Noninvasive Retinal Imaging

๐…๐ƒ๐€ ๐‚๐ฅ๐ž๐š๐ซ๐ฌ ๐Ž๐œ๐ฎ๐Œ๐ž๐ญ ๐๐ž๐š๐œ๐จ๐ง ๐Ÿ๐จ๐ซ ๐๐จ๐ง๐ข๐ง๐ฏ๐š๐ฌ๐ข๐ฏ๐ž ๐‘๐ž๐ญ๐ข๐ง๐š๐ฅ ๐ˆ๐ฆ๐š๐ ๐ข๐ง๐ 

๐Ÿ‘ OcuSciences has received FDA clearance for the OcuMet Beacon, a noninvasive imaging device that assesses retinal health without dyes, injections, or direct eye contact. Using autofluorescence (AF) and infrared (IR) signals, the Beacon offers a fast, patient-friendly alternative for detecting retinal disease.

๐Ÿ‘จโ€โš•๏ธ Backed by peer-reviewed studies and set to be featured at ARVO 2025, the OcuMet Beacon is now ready for clinical use across the U.S.โ€”marking a major step forward in early, comfortable retinal diagnostics.